UroView

Mark Emberton, BSc, MBBS, FRSC (Urol), MD, FMedSci, provides a historical perspective on treatment options for clinically localized prostate cancer, reviews emerging focal therapy options including HIFU, and discusses how focal therapy has impacted the field.

John J. Kowalczyk, DO, FACOS, shares his experience and perspectives on urology practice management and implementing software tools to improve practice workflows.

Stephen J. Freedland, MD, provides an overview of the diagnosis and staging of high-risk, clinically localized prostate cancer and explains how genomic testing helps inform risk stratification and treatment-decision making in his clinical practice.

This Uroview features discussion between Dr. Alexandra Rogers and Dr. Scott MacDiarmid about current and emerging treatments for overactive bladder, with a focus on implantable tibial nerve stimulation devices in this space.

Expert perspectives on the use of saw palmetto extracts to manage patients with benign prostatic hyperplasia and lower urinary tract symptoms.

Robert Dreicer, MD, provides an overview of advances in the treatment of metastatic castration-resistant prostate cancer (mCRPC) and available and emerging second-line treatment options for mCRPC.

Steven Finkelstein, MD, DABR, FACRO, and Louis J. Mazzarelli, MD, react to the article, “A Prospective Head-to-Head Comparison of 18F-Fluciclovine With 68Ga-PSMA-11 in Biochemical Recurrence of Prostate Cancer in PET/CT,” by Pernthaler B, et al.

Kyle Wood, MD, reviews currently available treatment options for enteric hyperoxaluria and the importance of disease education.

Two experts in urology provide a discussion on currently available screening and risk assessment tools in prostate cancer and emphasize the importance of early detection.